Use Of Fragmin In Hemodialysis

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Dalteparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

• chronic renal failure on hemodialysis

Exclusion Criteria:

• significant comorbidities that would prevent a patient from completing the trial